title: [Hormonal therapy for advanced prostate cancer: current status and issues].
abstract: For advanced prostate cancer, hormonal therapy has been utilized as the first choice of treatment. In general, initial hormonal therapy consists of androgen deprivation therapy by means of bilateral orchiectomy, LHRH agonist or LHRH antagonist. It has been attempted to improve efficacy of hormonal therapy by several methods including combined androgen blockade (CAB: castration+antiandrogen), intermittent hormonal therapy, or chemohormonal therapy using docetaxel. The results of clinical trials demonstrated benefit of each hormonal therapy in the selected patients with advanced prostate cancer. In future, it is expected that personalized hormonal therapy would be established based on understanding of characteristics and selection of good candidates for several types of hormonal therapies.
authors.forename: Koichiro
authors.initials: K
authors.lastname: Akakura
mesh_terms: D000726:Androgen Antagonists / Q000627:therapeutic use*; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D006801:Humans; D008297:Male; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D009919:Orchiectomy; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery
chemical_list: D000726:Androgen Antagonists; D018931:Antineoplastic Agents, Hormonal